Magnesium Salt, a Simple Strategy to Improve Methadone Analgesia in Chronic Pain: An Isobolographic Preclinical Study in Neuropathic Mice

González, Valeria; Cazanga, Victoria; Hernández, Alejandro; Constandil, Luís

doi:10.3389/fphar.2020.00566

Cited by 3 publications

(3 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, in the case of poorly controlled pain despite strong opioid intake, blood magnesium levels should be checked. In experimental studies, magnesium sulphate enhances the effect of analgesics acting as NMDA receptor antagonists like ketamine and methadone [44]. Clinical studies are needed to support these experimental observations.…”

Section: Optimizing Opioid Utilisation When Pain Remains Poorly Contr...mentioning

confidence: 99%

Cancer Pain Management: A Narrative Review of Current Concepts, Strategies, and Techniques

2023

View full text Add to dashboard Cite

Pain is frequently reported during cancer disease, and it still remains poorly controlled in 40% of patients. Recent developments in oncology have helped to better control pain. Targeted treatments may cure cancer disease and significantly increase survival. Therefore, a novel population of patients (cancer survivors) has emerged, also enduring chronic pain (27.6% moderate to severe pain). The present review discusses the different options currently available to manage pain in (former) cancer patients in light of progress made in the last decade. Major progress in the field includes the recent development of a chronic cancer pain taxonomy now included in the International Classification of Diseases (ICD-11) and the update of the WHO analgesic ladder. Until recently, cancer pain management has mostly relied on pharmacotherapy, with opioids being considered as the mainstay. The opioids crisis has prompted the reassessment of opioids use in cancer patients and survivors. This review focuses on the current utilization of opioids, the neuropathic pain component often neglected, and the techniques and non-pharmacological strategies available which help to personalize patient treatment. Cancer pain management is now closer to the management of chronic non-cancer pain, i.e., “an integrative and supportive pain care” aiming to improve patient’s quality of life.

show abstract

Section: Optimizing Opioid Utilisation When Pain Remains Poorly Contr...mentioning

confidence: 99%

Cancer Pain Management: A Narrative Review of Current Concepts, Strategies, and Techniques

2023

View full text Add to dashboard Cite

show abstract

“…Consequently, in case of poorly controlled pain despite strong opioid intake, blood magnesium levels should be checked. In experimental studies, magnesium sulfate enhance the effect of analgesics acting as NMDA receptor antagonists like ketamine and methadone [43].…”

Section: Opioids In Cancer Pain Management: An Update Of the Mainstay...mentioning

confidence: 99%

Cancer Pain Management - Current Concepts, Strategies and Management Techniques

Mestdagh¹,

Steyaert²,

Lavand’homme³

2023

Preprint

View full text Add to dashboard Cite

Pain is frequently reported during cancer disease, and still remains poorly controlled in 40% of patients. Recent developments in oncology have helped to better control pain. Targeted treatments may cure cancer disease and significantly increase survival. Thereby, a novel population of patients (cancer survivors) has emerged, also enduring chronic pain (27.6% moderate to severe pain). The present review discuss the different options currently available to manage pain in (former) cancer patients in the light of progress made in the last decade. Major progress in the field are recent development of a chronic cancer pain taxonomy now included in International Classification of Diseases (ICD-11) and update of WHO analgesic ladder. Until recently, cancer pain management has mostly relied on pharmacotherapy, opioids being considered as mainstay. The opioids crisis has prompted the reassessment of opioids use, both in cancer patients and cancer survivors. The review focuses on the current utilization of opioids, on the neuropathic pain component often neglected and on techniques and non-pharmacological strategies available which help to personalize patient’s treatment. Cancer pain management is now closer to the management of chronic non-cancer pain i.e. “an integrative pain care” aiming to improve patient’s quality of life.

show abstract

“…The antinociceptive interaction of rosuvastatin with duloxetine in mice with paclitaxelinduced neuropathy was performed by isobolographic analysis, as described elsewhere [76][77][78]. The isobologram is a graphic method that involves calculating the theoretical additive dose of two drugs for producing a determined level of effect, and the statistical comparison with the combination dose that causes the same effect experimentally [24,37,38].…”

Section: Isobolographic Analysis Of the Interaction Of Rosuvastatin W...mentioning

confidence: 99%

Rosuvastatin Synergistically Enhances the Antinociceptive Efficacy of Duloxetine in Paclitaxel-Induced Neuropathic Pain in Mice

Lobos,

Lux,

Zepeda

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

Paclitaxel, a widely used cancer chemotherapeutic agent, has high incidence of neurotoxicity associated with the production of neuropathic pain, for which only duloxetine has shown significant but moderate analgesic effect. Since statins, classically used to reduce hypercholesterolemia, have shown antinociceptive effect in preclinical studies on neuropathic pain, we studied whether the antinociceptive efficacy of duloxetine could be synergistically potentiated by rosuvastatin in a model of paclitaxel-induced neuropathy in mice. The astrocytic and microglial responses in the spinal cord of paclitaxel-treated mice were also assessed by measuring GFAP and CD11b proteins, respectively. Paclitaxel treatment did not impair motor coordination and balance in rotarod testing. Rosuvastatin, duloxetine, and the rosuvastatin/duloxetine combination (combined at equieffective doses) dose-dependently decreased mechanical allodynia (ED30, von Frey testing) and thermal hyperalgesia (ED50, hot plate testing) in paclitaxel-treated mice. Isobolographic analysis showed a superadditive interaction for rosuvastatin and duloxetine, as both the ED30 and ED50 for the rosuvastatin/duloxetine combination contained only a quarter of each drug compared to the individual drugs. The rosuvastatin/duloxetine combination reversed paclitaxel-induced GFAP overexpression, indicating that such effects might depend in part on astrocyte inactivation. Results suggest that statins could be useful in synergistically enhancing the efficacy of duloxetine in some chemotherapy-induced neuropathic conditions.

show abstract

Magnesium Salt, a Simple Strategy to Improve Methadone Analgesia in Chronic Pain: An Isobolographic Preclinical Study in Neuropathic Mice

Cited by 3 publications

References 62 publications

Cancer Pain Management: A Narrative Review of Current Concepts, Strategies, and Techniques

Cancer Pain Management: A Narrative Review of Current Concepts, Strategies, and Techniques

Cancer Pain Management - Current Concepts, Strategies and Management Techniques

Rosuvastatin Synergistically Enhances the Antinociceptive Efficacy of Duloxetine in Paclitaxel-Induced Neuropathic Pain in Mice

Contact Info

Product

Resources

About